腺病毒疫苗市场报告：2030 年趋势、预测与竞争分析

腺病毒疫苗趋势与预测

预计到 2030 年，全球腺病毒疫苗市场将达到 14 亿美元，2024 年至 2030 年复合年增长率为 7.5%。该市场的主要驱动因素是癌症基因疗法疫苗接种需求的激增以及製药公司疫苗接种需求的激增。全球腺病毒疫苗市场的未来看起来充满希望，研究/学术、实验室和製药/生物技术市场存在机会。

Lucintel 预测，7 型疫苗预计将在预测期内出现强劲增长，因为它们价格实惠且能提供即时免疫力。

由于腺病毒感染的高流行和人口的持续增长，预计北美在预测期内将经历最高的增长。

腺病毒疫苗市场的新趋势

腺病毒疫苗市场正在透过各种新兴趋势不断发展，成为创新和市场成长的关键驱动力。这些趋势反映了疫苗技术的不断发现和世界对抗感染疾病的斗争。

• 下一代疫苗：下一代腺病毒疫苗的开发旨在提高功效、安全性和递送能力。这可以从基于载体的疫苗和旨在增强免疫反应同时减少副作用和其他副作用的新颖配方等创新中看到。
• 疫苗产能扩张：全球疫苗产能扩张趋势明显。为了确保腺病毒疫苗的稳定供应，特别是在 COVID-19 大流行期间，各国正在投资先进的生产设施。
• 全球疫苗分配：正在努力向低收入和中等收入国家提供腺病毒疫苗，并实现公平的全球疫苗分配。政府、非政府组织和製药公司之间的伙伴关係是实现广泛获取的趋势之一。
• 监管改革：监管机构正在迅速实施更灵活的腺病毒疫苗核准程序。这反映了公共卫生危机的紧迫性以及製造商将新药迅速推向市场的需要。
• 研发合作：腺病毒疫苗市场的主要趋势之一是研究机构、生技公司和政府之间加强合作。此类伙伴关係正在引领创新并加快疫苗开发的步伐。

这些趋势正在透过推动创新、扩大生产能力和确保全球疫苗可及性来重塑腺病毒疫苗市场。为了应对新出现的感染疾病和公共卫生需求，市场正在迅速变化。

腺病毒疫苗市场近期趋势

腺病毒疫苗市场的最新发展集中在全球公共卫生需求驱动的研究、贸易和供应方面的显着进展。

• 扩大生产能力：领先的疫苗製造商正在提高生产能力，以满足全球对腺病毒疫苗不断增长的需求。此次扩建包括新设施和现有设施的改进，以增加产量并确保疫苗的供应。
• 政府资助和支持：世界各国政府正在投入巨额资金用于腺病毒疫苗的开发。此类财政支持可以采取多种形式，包括津贴、补贴或加速监管核准，以帮助疫苗快速成长。
• 合作研究计画：与製药公司的伙伴关係也正在推动腺病毒疫苗开发领域的创新。这些伙伴关係旨在提高疫苗的效率、管理和可近性。
• 全球经销伙伴：公司正在建立合作伙伴关係，以促进这种疫苗的全球供应，特别是在低收入和中等收入国家。这些倡议的具体目的是缩小公平差距，并为最需要的人提供疫苗。

这些进步显着改善了腺病毒疫苗产业，并实现了疫苗的有效生产、开发和交付，以应对全球公共卫生挑战。

腺病毒疫苗市场的策略性成长机会

在技​​术进步和全球需求不断增长的推动下，腺病毒疫苗市场在各种应用中存在一些策略性成长机会。

• 儿童疫苗接种计划 加强儿童疫苗接种计划将是成长的重要槓桿。这需要开发儿科专用腺病毒疫苗并将其纳入国家免疫计划，以满足重要的儿童安全要求。
• 旅行和军事疫苗接种：针对旅行者和军事相关人员接种腺病毒疫苗是一项可以带来持续成长的策略。由于这些人群更容易感染腺病毒，因此可以专门针对他们配製疫苗。
• 疫苗组合策略：将腺病毒疫苗与其他疫苗组合成单一剂量代表未来成长的机会。特别是在资源有限的环境中，这种免疫方法可以简化时间表并增加覆盖范围。
• 流行病对策：预计未来腺病毒疫苗在流行病对策中的使用将会增加。为了全球卫生安全，需要储备疫苗并在疫情爆发时迅速部署。
• 个人化疫苗：基于腺病毒开发与个人基因谱相符的个人化疫苗是业务扩张的新来源。希望将免疫反应与每个人的基因相匹配将提高疫苗的有效性。

这些成长策略正在支持腺病毒疫苗市场的开拓和扩大。专注于市场的关键应用可能会产生满足关键公共卫生需求的解决方案，类似于全球疫苗接种工作。

腺病毒疫苗市场驱动因素与挑战

腺病毒疫苗产业受到许多驱动因素和挑战的影响，包括技术进步、监管问题和经济状况。

推动腺病毒疫苗市场的因素是：

1.技术进步：市场是由基于病毒载体的疫苗和创新的递送系统等技术所推动的。这些进展提高了疫苗的功效和安全性，并改善了疫苗的获取，导致其广泛接受。

2.提高公共卫生意识：人们对疫苗接种在预防感染疾病中作用的认识不断提高，正在推动对腺病毒疫苗的需求。公共卫生宣传活动和教育计划推动了疫苗使用的增加。

3. 政府支持：政府对腺病毒疫苗的开发与销售给予大力支持。这包括津贴、拨款和更快的核准流程，以缩短这些产品的上市时间。

4.全球疾病负担：全球疾病负担的增加，包括腺病毒引起的感染疾病，正在推动市场发展。预防疫情爆发并降低发病率和死亡率的需要导致对疫苗等预防措施的投资增加。

5. 大流行应对：在 COVID-19 大流行期间，腺病毒疫苗接种在全球大流行防范中的重要性已变得显而易见。

腺病毒疫苗市场面临的挑战包括：

1. 监管障碍：由于世界各地存在复杂多元的法规环境，疫苗开发商面临各种挑战。国际经营的公司必须遵守许多法规。

2. 疫苗犹豫：儘管疫苗接种很重要，但这是相当大的挑战之一。非洲正遭受严重的黄热病流行，因为许多成年人在儿童时期没有接种疫苗。

3.供应链限制：腺病毒疫苗的稳定供应仍然是一个障碍，特别是在新兴国家。也有人避免接种疫苗，因为他们认为疫苗有害。

腺病毒疫苗市场的成长和开拓有许多驱动因素和挑战。虽然腺病毒疫苗市场是由这些技术突破和政府支持推动的，但它还需要解决阻碍大规模采用和供应的监管障碍和疫苗犹豫等问题。

腺病毒疫苗细分市场

本研究按类型、应用和地区对全球腺病毒疫苗进行了预测。

腺病毒疫苗市场的国家展望

活性化的研发活动、对疫苗可预防疾病的认识不断提高以及全球应对新兴感染疾病的努力正在推动腺病毒疫苗市场的成长。中国、德国、印度、日本和美国等主要市场在疫苗技术进步、生产和分销方面取得了最新进展。

• 美国：腺病毒疫苗研究经费正在增加，特别是用于军事和公共卫生应变方面。强生公司正在扩大产能以满足国内和全球需求。
• 中国 中国今年的重点是腺病毒疫苗，特别是自 COVID-19 诞生以来。在政府的大力支持下，中国企业正在努力透过提高生产能力来提高疫苗的有效性，以提高疫苗在全国范围内的使用率。
• 德国 德国研究机构处于腺病毒疫苗研究的前沿，正在进行合作以提高疫苗接种和有效性。我们也有兴趣参与疫苗分配和扩大生产线的国际倡议。
• 印度 印度腺病毒疫苗的生产进展迅速。该国的法律规范涵盖政府对当地疫苗开发商的资助，旨在成为全球疫苗供应的核心参与者。
• 日本 在日本，生产下一代腺病毒疫苗时越来越关注提高安全性和有效性。我们也关注国内健康需求和先进的製造技术，以确保快速製造和分销。

常问问题

Q.1 腺病毒疫苗的市场规模有多大？

A1. 到2030年，全球腺病毒疫苗市场预计将达到14亿美元。

Q.2 腺病毒疫苗市场的成长预测如何？

A2. 预计2024年至2030年全球腺病毒疫苗市场将以7.5%的复合年增长率成长。

Q.3 影响腺病毒疫苗市场成长的关键驱动因素有哪些？

A3. 该市场的主要驱动因素是癌症基因治疗疫苗接种需求的激增以及製药公司疫苗接种需求的激增。

Q4.市场的主要细分市场是：

A4. 腺病毒疫苗市场的未来看起来充满希望，在研究/学术、实验室和製药/生物技术市场中存在着机会。

Q5.市场的主要企业是：

A5.主要企业如下：

• Novasep
• Charles River Laboratories
• Uniqure
• Waisman Biomanufacturing
• Creative-Biogene
• Aldevron
• Addgene
• Thermo Fisher Scientific
• Fujifilm Corporation
• Spark Therapeutics

Q6.未来最大的细分市场是什么？

A6.Lucintel 预计，由于 7 型疫苗价格实惠且能够提供即时免疫力，因此在预测期内将出现高速增长。

Q7. 未来五年预计哪些地区的市场成长最大？

A7. 由于腺病毒感染的高流行和人口的持续增长，预计北美在预测期内将出现最高的增长。

Q8. 可以客製化报告吗？

A8. 是的，Lucintel 提供 10% 的客製化服务，无需额外付费。

目录

第一章执行摘要

第二章全球腺病毒疫苗市场：市场动态

• 简介、背景、分类
• 供应链
• 产业驱动因素与挑战

第三章 2018-2030年市场趋势及预测分析

• 宏观经济趋势（2018-2023）与预测（2024-2030）
• 全球腺病毒疫苗市场趋势（2018-2023）与预测（2024-2030）
• 全球腺病毒疫苗市场，依类型
  • 4型疫苗
  • 7型疫苗
• 全球腺病毒疫苗市场按应用
  • 研究和学术
  • 研究所
  • 製药/生物技术

第四章 2018-2030年区域市场趋势及预测分析

• 全球腺病毒疫苗市场（按地区）
• 北美腺病毒疫苗市场
• 欧洲腺病毒疫苗市场
• 亚太腺病毒疫苗市场
• 其他区域腺病毒疫苗市场

第五章 竞争分析

• 产品系列分析
• 营运整合
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球腺病毒疫苗市场按类型分類的成长机会
  • 全球腺病毒疫苗市场成长机会（按应用）
  • 全球腺病毒疫苗市场成长机会（按地区）
• 全球腺病毒疫苗市场的新趋势
• 战略分析
  • 新产品开发
  • 全球腺病毒疫苗市场产能扩张
  • 全球腺病毒疫苗市场的併购与合资
  • 认证和许可

第七章主要企业概况

• Novasep
• Charles River Laboratories
  • uniQure
• Waisman Biomanufacturing
• Creative-Biogene
• Aldevron
• Addgene
• Thermo Fisher Scientific
• Fujifilm Corporation
• Spark Therapeutics

Adenovirus Vaccine Trends and Forecast

The future of the global adenovirus vaccine market looks promising with opportunities in the research and academic, laboratories, and pharmaceutical & biotechnology markets. The global adenovirus vaccine market is expected to reach an estimated $1.4 billion by 2030 with a CAGR of 7.5% from 2024 to 2030. The major drivers for this market are the rapidly increasing need for vaccinations in cancer gene therapies and surge in vaccination demand from pharmaceutical companies.

Lucintel forecasts that type 7 vaccine is expected to witness higher growth over the forecast period due to its affordability and ability to instantly confer immunity.

North America is expected to witness highest growth over the forecast period due to due to the high prevalence of adenovirus infection and continuous population growth in the region.

Emerging Trends in the Adenovirus Vaccine Market

The market of adenovirus vaccine is subject to evolution through various emerging trends, which are thus key drivers of innovation and market growth. These trends mirror the ongoing discoveries in vaccine technology and the global fight against infectious diseases.

• Next-Generation Vaccines: The development of next-generation adenovirus vaccines seeks to improve efficacy, safety, and delivery. This can be seen in innovations such as vector-based vaccines and novel formulations designed to enhance immune responses while reducing side effects or other adverse reactions.
• Vaccine Manufacturing Expansion: There is a significant trend towards expanding worldwide vaccine manufacturing ability. To ensure a steady supply of adenovirus vaccines, especially during the time of the COVID-19 pandemic, countries are investing in advanced manufacturing facilities.
• Global Vaccine Distribution: Efforts are being made towards ensuring that adenovirus vaccines are available in low- and middle-income countries for equitable global vaccine distribution. Partnerships between governments, NGOs, and pharmaceutical companies are among this trend to achieve widespread access
• Regulatory Innovation: Regulatory authorities have implemented more flexible procedures for approving adenovirus vaccines at an accelerated rate. This reflects the public health crises' urgency and the necessity of hastening introduction of new drugs into the market by manufacturers.
• Collaboration in Research and Development: One of the major trends in the adenovirus vaccine market is increased collaboration between research institutions, biotech companies, and governments. Such partnerships have led to innovation and quickened the pace of vaccine development.

By driving technological innovation, expanding manufacturing capacities, and ensuring global vaccine access, these trends are reshaping the adenovirus vaccine market. The market is changing fast to meet emerging infectious diseases and public health needs.

Recent Developments in the Adenovirus Vaccine Market

Recent happenings in the adenovirus vaccine market highlight remarkable advancements in research, trading, and delivery due to global public health needs.

• Manufacturing Capacity Expansion: Major vaccine manufacturers are now increasing their production capacities so that they can be able to serve the ever-growing global demand for adenovirus vaccines. This expansion includes building new facilities and upgrading existing ones to increase output and ensure vaccine availability.
• Funding by Government and Support: Governments worldwide have committed huge sums of money towards the development of an adenovirus vaccine. Such funding may take various forms including grants, subsidies, or fastened regulatory approvals aimed at ensuring quick growth of vaccines.
• Collaborative Research Initiatives: The inclusion of partnerships with pharmaceutical companies has also enhanced innovation within the field of adenovirus vaccine development. These partnerships aim to enhance vaccines' efficiency, means of being administered as well as accessibility.
• Global Distribution Partnerships: Companies have established alliances that facilitate the provision of this vaccine globally, especially in low- to middle-income countries. These initiatives aim to bridge the equity gap among other things bringing vaccines closer to those who need them most.

These advancements are resulting in considerable improvements within the Adenovirus Vaccine industry, ensuring that vaccines are produced, developed, and delivered effectively to meet worldwide public health issues.

Strategic Growth Opportunities for Adenovirus Vaccine Market

Several strategic growth opportunities exist in the adenovirus vaccine market across different applications, impelled by technology advancements and heightened worldwide demand.

• Pediatric Vaccination Programs: Enhancing pediatric vaccination programs presents important avenues for growth. This entails developing adenovirus vaccines that are specific to children and can be included in national immunization programs thereby meeting a critical requirement about early childhood safety.
• Travel and Military Vaccination: Directing adenovirus vaccination at travelers and military personnel is one of the strategies that could lead to sustained growth. These cohorts have an elevated likelihood of contracting adenovirus, so there can be a formulation of vaccines catering specifically to them.
• Vaccine Combination Strategies: Merging adenovirus vaccines with other vaccines into single doses means opportunities for future growth. In resource-constrained environments particularly, this way of immunizing people simplifies schedules and increases coverage with further consequences.
• Pandemic Preparedness: The use of adenovirus vaccines for pandemic preparedness is poised for growth. Global health security demands the creation of vaccine stockpiles and their swift deployment during outbreaks.
• Personalized Vaccines: The development of adenovirus-based personalized vaccines tailored to individual genetic profiles represents an emerging source of business expansion. Vaccine efficacy is expected to increase through this strategy by matching immune responses to each individual's genetics.

These growth strategies are what are fueling the development and enlargement of the adenovirus vaccine market. By focusing on key applications in the market, there will be solutions to critical public health needs as well as global vaccination efforts.

Adenovirus Vaccine Market Driver and Challenges

The adenovirus vaccine industry is affected by a number of drivers and challenges, which include technological progress, regulatory concerns and economic conditions.

The factors responsible for driving the adenovirus vaccine market include:

1. Advancement in Technology : The market has been driven by technology including vaccines based on viral vectors and innovative delivery systems. These developments have improved vaccine efficacy and safety as well as access to them leading to their widespread acceptance.

2. Increased Public Awareness of Health: The growing awareness about the role of immunization in preventing infectious diseases is driving up demand for adenovirus vaccines. This rise in the use of vaccines has been boosted through public health campaigns and education programs.

3. Government Support: Notable support from governments has driven the development and distribution of adenovirus vaccines. This includes grants, subsidies and accelerated approval processes which speed up time-to-market for these products.

4. Global Burden Of Disease: The Market Is Driven By Increasing Global Burden Of Infectious Diseases Including Those Caused By Adenoviruses. Need to prevent outbreaks and reduce morbidity/mortality has led to greater investment in preventative measures such as vaccines.

5. Pandemic Response: The significance of adenoviral vaccination under global pandemic preparedness was revealed by COVID-19 outbreak that prompted more investments into developing vaccines with large stockpiles for quick response capacity buildup.

Challenges in the adenovirus vaccine market are:

1. Regulatory Hurdles: The problem of navigating through different complicated and varying regulatory environments in the world means that vaccine developers face a challenge. There are numerous rules which have to be followed by companies operating internationally.

2. Vaccine Hesitancy: Still, despite the importance of vaccination, it is one of the considerable challenges. This has seen many adults in Africa suffering from severe yellow fever outbreaks because they were never vaccinated as children.

3. Supply Chain Constraints: Steady supply of adenovirus vaccines, especially in developing countries remains an obstacle while new countries continue to demand for vaccines. Some people have been avoiding vaccinations because they believe that such drugs are harmful.

There are several driving factors and challenges that shape the adenovirus vaccine market on its way to growth and development. The market is being driven ahead by these technological breakthroughs as well as government assistance but there has to be a solution for issues like regulatory hurdles and vaccine hesitancy which hinderize uptake and availability of vaccines on large scale.

List of Adenovirus Vaccine Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies adenovirus vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the adenovirus vaccine companies profiled in this report include-

• Novasep
• Charles River Laboratories
• Uniqure
• Waisman Biomanufacturing
• Creative-Biogene
• Aldevron
• Addgene
• Thermo Fisher Scientific
• Fujifilm Corporation
• Spark Therapeutics

Adenovirus Vaccine by Segment

The study includes a forecast for the global adenovirus vaccine by type, application, and region.

Adenovirus Vaccine Market by Type [Analysis by Value from 2018 to 2030]:

• Type 4 Vaccine
• Type 7 Vaccine

Adenovirus Vaccine Market by Application [Analysis by Value from 2018 to 2030]:

• Research and Academic
• Laboratories
• Pharmaceutical & Biotechnology

Adenovirus Vaccine Market by Region [Analysis by Value from 2018 to 2030]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Adenovirus Vaccine Market

Increasing research and development activities, increasing awareness of vaccine-preventable diseases, and global efforts to address emerging infectious diseases are driving the growth of the adenovirus vaccine market. In terms of vaccine technology advancement, production, and distribution there have been recent developments in key markets such as those in China, Germany, India, Japan, and The United States.

• United States: There has been increased adenovirus vaccine research funding, particularly for the military and public health response. New vaccine candidates have received accelerated approvals from FDA while Johnson & Johnson is expanding its production capacity to satisfy domestic demand as well as global ones.
• China: This year China has focused on adenovirus vaccines especially after COVID-19 came into being. Chinese firms are working on making vaccines more effective by improving their manufacturing capacity with considerable government backing that promotes availability across the country.
• Germany: Institutions in Germany have been at the forefront of adenovirus vaccine studies where collaborative research is being conducted to advance ways towards bettering vaccination delivery and efficacy. The country is also interested in expanding production lines besides joining international initiatives on the distribution of vaccines.
• India: India is progressing swiftly in the production of adenovirus vaccines on account of its huge manufacturing capacity. The country's regulatory framework covers government funding for local vaccine developers, which aims to position it as a central player in global vaccine supplies.
• Japan: In Japan, more attention is given to safety and efficacy improvements when making future-generation adenovirus vaccines. It also focuses on advanced manufacturing technologies to ensure quick production and distribution emphasizing domestic health needs.

Features of the Global Adenovirus Vaccine Market

Market Size Estimates: Adenovirus vaccine market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.

Segmentation Analysis: Adenovirus vaccine market size by type, application, and region in terms of value ($B).

Regional Analysis: Adenovirus vaccine market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different types, applications, and regions for the adenovirus vaccine market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the adenovirus vaccine market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

FAQ

Q.1 What is the adenovirus vaccine market size?

Answer: The global adenovirus vaccine market is expected to reach an estimated $1.4 billion by 2030.

Q.2 What is the growth forecast for adenovirus vaccine market?

Answer: The global adenovirus vaccine market is expected to grow with a CAGR of 7.5% from 2024 to 2030.

Q.3 What are the major drivers influencing the growth of the adenovirus vaccine market?

Answer: The major drivers for this market are the rapidly increasing need for vaccinations in cancer gene therapies and surge in vaccination demand from pharmaceutical companies.

Q4. What are the major segments for adenovirus vaccine market?

Answer: The future of the adenovirus vaccine market looks promising with opportunities in the research and academic, laboratories, and pharmaceutical & biotechnology markets.

Q5. Who are the key adenovirus vaccine market companies?

Answer: Some of the key adenovirus vaccine companies are as follows:

• Novasep
• Charles River Laboratories
• Uniqure
• Waisman Biomanufacturing
• Creative-Biogene
• Aldevron
• Addgene
• Thermo Fisher Scientific
• Fujifilm Corporation
• Spark Therapeutics

Q6. Which adenovirus vaccine market segment will be the largest in future?

Answer: Lucintel forecasts that type 7 vaccine is expected to witness higher growth over the forecast period due to its affordability and ability to instantly confer immunity.

Q7. In adenovirus vaccine market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period due to due to the high prevalence of adenovirus infection and continuous population growth in the region.

Q.8 Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the adenovirus vaccine market by type (type 4 vaccine and type 7 vaccine), application (research and academic, laboratories, and pharmaceutical & biotechnology), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?
• Market Report

Table of Contents

1. Executive Summary

2. Global Adenovirus Vaccine Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

• 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
• 3.2. Global Adenovirus Vaccine Market Trends (2018-2023) and Forecast (2024-2030)
• 3.3: Global Adenovirus Vaccine Market by Type
  • 3.3.1: Type 4 Vaccine
  • 3.3.2: Type 7 Vaccine
• 3.4: Global Adenovirus Vaccine Market by Application
  • 3.4.1: Research and Academic
  • 3.4.2: Laboratories
  • 3.4.3: Pharmaceutical & Biotechnology

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

• 4.1: Global Adenovirus Vaccine Market by Region
• 4.2: North American Adenovirus Vaccine Market
  • 4.2.1: North American Adenovirus Vaccine Market by Type: Type 4 Vaccine and Type 7 Vaccine 4.2.2: North American Adenovirus Vaccine Market by Application: Research and Academic, Laboratories, and Pharmaceutical & Biotechnology
• 4.3: European Adenovirus Vaccine Market
  • 4.3.1: European Adenovirus Vaccine Market by Type: Type 4 Vaccine and Type 7 Vaccine
  • 4.3.2: European Adenovirus Vaccine Market by Application: Research and Academic, Laboratories, and Pharmaceutical & Biotechnology
• 4.4: APAC Adenovirus Vaccine Market
  • 4.4.1: APAC Adenovirus Vaccine Market by Type: Type 4 Vaccine and Type 7 Vaccine
  • 4.4.2: APAC Adenovirus Vaccine Market by Application: Research and Academic, Laboratories, and Pharmaceutical & Biotechnology
• 4.5: ROW Adenovirus Vaccine Market
  • 4.5.1: ROW Adenovirus Vaccine Market by Type: Type 4 Vaccine and Type 7 Vaccine
  • 4.5.2: ROW Adenovirus Vaccine Market by Application: Research and Academic, Laboratories, and Pharmaceutical & Biotechnology

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Adenovirus Vaccine Market by Type
  • 6.1.2: Growth Opportunities for the Global Adenovirus Vaccine Market by Application
  • 6.1.3: Growth Opportunities for the Global Adenovirus Vaccine Market by Region
• 6.2: Emerging Trends in the Global Adenovirus Vaccine Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Adenovirus Vaccine Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Adenovirus Vaccine Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Novasep
• 7.2: Charles River Laboratories
  • 7.1.1: uniQure
• 7.4: Waisman Biomanufacturing
• 7.5: Creative-Biogene
• 7.6: Aldevron
• 7.7: Addgene
• 7.8: Thermo Fisher Scientific
• 7.9: Fujifilm Corporation
• 7.10: Spark Therapeutics